ArriVent BioPharma Q3 2026 Earnings Date & Estimates

ArriVent BioPharma (NASDAQ:AVBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations. Furmonertinib has been approved in China for certain EGFR-mutated non-small cell lung cancer indications and is being evaluated by ArriVent in additional patient populations and geographies.

The company obtained rights to develop and commercialize furmonertinib outside Greater China through a partnership with Allist Pharmaceuticals. ArriVent is headquartered in the United States and is advancing its programs through clinical trials intended to support potential regulatory submissions in the United States and other international markets. Its pipeline and development strategy are centered on targeted oncology therapies for patients whose tumors have actionable genetic alterations.